2024 annual financial data
Ernexa Therapeutics 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was -2,720.96%.
Operating income was -15,674,000 USD and net income was -44,539,000 USD.
Operating cash flow was -15,836,000 USD.
Get free Ernexa Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 582,000 USD
- Operating income
- -15,674,000 USD
- Net income
- -44,539,000 USD
- Operating cash flow
- -15,836,000 USD